Benzinga | Apr 19, 2021 04:02PM EDT

Incyte And MorphoSys Announce First Patient Dosed In Phase 3 inMIND Study Evaluating Addition Of Tafasitamab To Lenalidomide And Rituximab In Relapsed Or Refractory Follicular Or Marginal Zone Lymphoma

Incyte (NASDAQ:INCY) and MorphoSys AG ((FSE: MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) today announced the first patient has been dosed in the placebo-controlled Phase 3 inMIND study evaluating the efficacy and safety of tafasitamab or placebo in combination with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL).